Pulike Biological Engineering, Inc.

SHSE:603566 Stock Report

Market Cap: CN¥4.3b

Pulike Biological Engineering Valuation

Is 603566 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603566 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603566 (CN¥12.45) is trading below our estimate of fair value (CN¥13.98)

Significantly Below Fair Value: 603566 is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603566?

Other financial metrics that can be useful for relative valuation.

603566 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA16.4x
PEG Ratio1.2x

Price to Earnings Ratio vs Peers

How does 603566's PE Ratio compare to its peers?

The above table shows the PE ratio for 603566 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.9x
301211 Hubei Biocause Heilen Pharmaceutical
24.6xn/aCN¥4.3b
603998 Hunan Fangsheng Pharmaceutical
24.3x22.6%CN¥4.7b
600479 ZhuZhou QianJin PharmaceuticalLtd
13.3xn/aCN¥4.3b
300194 Fuan Pharmaceutical (Group)
17.3xn/aCN¥4.7b
603566 Pulike Biological Engineering
31.1x26.2%CN¥4.3b

Price-To-Earnings vs Peers: 603566 is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the peer average (19.9x).


Price to Earnings Ratio vs Industry

How does 603566's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 603566 is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the CN Pharmaceuticals industry average (28.2x).


Price to Earnings Ratio vs Fair Ratio

What is 603566's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603566 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.1x
Fair PE Ratio24.2x

Price-To-Earnings vs Fair Ratio: 603566 is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the estimated Fair Price-To-Earnings Ratio (24.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603566 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥12.45
CN¥18.56
+49.1%
16.0%CN¥22.00CN¥15.25n/a4
Jul ’25CN¥13.80
CN¥19.94
+44.5%
11.6%CN¥22.00CN¥16.00n/a4
Jun ’25CN¥16.95
CN¥20.24
+19.4%
9.0%CN¥22.00CN¥17.20n/a4
May ’25CN¥17.43
CN¥20.24
+16.1%
9.0%CN¥22.00CN¥17.20n/a4
Apr ’25CN¥18.21
CN¥25.07
+37.7%
22.4%CN¥30.00CN¥17.20n/a3
Mar ’25CN¥16.50
CN¥27.23
+65.1%
9.7%CN¥30.00CN¥23.70n/a3
Feb ’25CN¥15.24
CN¥28.18
+84.9%
9.9%CN¥31.00CN¥23.70n/a4
Jan ’25CN¥22.65
CN¥28.18
+24.4%
9.9%CN¥31.00CN¥23.70n/a4
Dec ’24CN¥21.13
CN¥28.18
+33.3%
9.9%CN¥31.00CN¥23.70n/a4
Nov ’24CN¥20.24
CN¥28.18
+39.2%
9.9%CN¥31.00CN¥23.70n/a4
Oct ’24CN¥21.31
CN¥28.18
+32.2%
9.9%CN¥31.00CN¥23.70n/a4
Sep ’24CN¥22.09
CN¥28.18
+27.5%
9.9%CN¥31.00CN¥23.70n/a4
Aug ’24CN¥23.36
CN¥28.90
+23.7%
12.8%CN¥32.00CN¥23.70n/a3
Jul ’24CN¥23.25
CN¥28.90
+24.3%
12.8%CN¥32.00CN¥23.70CN¥13.803
Jun ’24CN¥24.26
CN¥30.67
+26.4%
4.1%CN¥32.00CN¥29.00CN¥16.953
May ’24CN¥26.58
CN¥30.67
+15.4%
4.1%CN¥32.00CN¥29.00CN¥17.433
Apr ’24CN¥28.42
CN¥30.50
+7.3%
4.9%CN¥32.00CN¥29.00CN¥18.212
Mar ’24CN¥30.43
CN¥30.50
+0.2%
4.9%CN¥32.00CN¥29.00CN¥16.502
Feb ’24CN¥29.03
CN¥30.50
+5.1%
4.9%CN¥32.00CN¥29.00CN¥15.242
Jan ’24CN¥27.36
CN¥30.50
+11.5%
4.9%CN¥32.00CN¥29.00CN¥22.652
Dec ’23CN¥28.21
CN¥30.50
+8.1%
4.9%CN¥32.00CN¥29.00CN¥21.132
Nov ’23CN¥28.05
CN¥28.05
0%
14.1%CN¥32.00CN¥24.10CN¥20.242
Oct ’23CN¥28.32
CN¥31.05
+9.6%
22.4%CN¥38.00CN¥24.10CN¥21.312
Sep ’23CN¥29.76
CN¥31.05
+4.3%
22.4%CN¥38.00CN¥24.10CN¥22.092
Aug ’23CN¥29.00
CN¥26.87
-7.4%
16.2%CN¥33.00CN¥23.50CN¥23.363
Jul ’23CN¥27.06
CN¥26.87
-0.7%
16.2%CN¥33.00CN¥23.50CN¥23.253

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.